Anivive Expands Specialty Diagnostics Lab to Accommodate Increased Demand for Services

• World-renowned experts Dr. Barb Powers and Dr. Jeff Edwards lead specialty pathology services
• Offering 1:1 consultations and shorter turnaround times than most national labs
• Accessible, accurate and affordable diagnostics with no-contract pricing

LONG BEACH, Calif., March 5, 2025 /PRNewswire/ -- Anivive, a software-driven pet health company, announces the expansion of its Long Beach lab to accommodate increased demand for its specialty pathology services through Vidium, a leader in veterinary diagnostics. This interest has been credited to the unique expertise offered by Vidium's specialty pathology leadership team, led by anatomic pathologists Dr. Barb Powers and Dr. Jeff Edwards.

Anivive achieved remarkable revenue growth in 2024, reflecting its leadership in the rapidly evolving field of cancer diagnostics. As a result, the company has invested in its Long Beach lab, which handles genomic sequencing for its SearchLight DNA™ diagnostics. The improvements include state-of-the-art Illumina next-generation sequencing equipment, the latest Hamamatsu advanced high-resolution digital slide scanner, and training for lab personnel to support the extensive range of histology, cytology and genomic sequencing services.

"Anivive is thrilled to have the very best veterinary pathologists leading our specialty pathology services," said Dr. Chad Dodd, Chief Commercial Officer of Anivive. "With over 110 years of combined experience in veterinary pathology, they truly are the experts in their field. It's no wonder clinicians are lining up to work with them."

Barb Powers, DVM, PhD, DACVP, is a key opinion leader in veterinary oncopathology. Her impact on the industry has been felt through four decades of experience as a board-certified pathologist and researcher in academia and veterinary associations. Dr. Powers served as the Director of the Colorado State University Veterinary Diagnostic Lab for 22 years and has authored over 200 articles on small animal oncology, radiation pathology, and orthopedic pathology. She holds a DVM from Purdue University and completed her pathology residency and PhD at Colorado State University. Dr. Powers also has additional expertise in equine endometrial pathology and oral and orthopedic pathology, and will be contributing author of an upcoming veterinary oncology textbook.

Jeff Edwards, DVM, MPH, MRCVS, DACVP, brings 35 years of experience in diagnostic pathology.  As an exceptional pathology consultant and proven leader, prior to joining Anivive, he spent most of his career as Chief of Anatomic Pathology for a leading global veterinary referral laboratory. He has served as a diagnostic veterinary pathologist at NIH Oregon Primate Research and the Texas A&M Veterinary Medical Diagnostic Laboratory. He holds a DVM from Texas A&M University College of Veterinary Medicine, a MPH degree from Johns Hopkins School of Public Health, and completed a post-doctoral fellowship in Comparative Pathology at Johns Hopkins School of Medicine in Baltimore, MD. Dr. Edwards is board-certified and has led significant advancements in digital pathology technology and artificial intelligence projects in anatomic pathology.

Jennifer Steinberg, DVM, DACVP, has almost 2 decades of experience providing diagnostic clinical pathology services. Before specializing in digital cytology services, she worked as a diagnostic pathologist for a leading global, commercial laboratory for 11 and a half years. Dr. Steinberg has taught at the veterinary colleges at Tufts University, University of Pennsylvania, and Lincoln Memorial University. She continues to support resident training at Auburn University and the University of Pennsylvania. Dr. Steinberg is an ASVCP member, serving on the quality assurance and standards subcommittee on digital cytology and hematology. She holds a DVM from Tufts University, completed an internship in Small Animal Medicine & Surgery at Schwarzman Animal Medical Center, and a residency in Clinical Pathology at Colorado State University and Tufts University. Dr. Steinberg is a board-certified Clinical Pathologist.

Susan Fielder, DVM, MS, DACVP, has provided diagnostic cytology services for over 20 years. She has worked as a diagnostic pathologist for the Texas Veterinary Medical Diagnostic Laboratory, among other prestigious diagnostic providers. Dr. Fielder is a Clinical Associate Professor at Oklahoma State University. She holds a DVM from Oklahoma State University, completed an internship in Small Animal Medicine & Surgery at Kansas State University, and a residency in Clinical Pathology at Oklahoma State University. Dr. Fielder is a board-certified Clinical Pathologist.

Drs. Powers, Edwards, Steinberg, and Fielder are available for primary consultations and second-opinion services to help support any of your specialty pathology service needs. For more information, please visit vidiumah.com.

About Anivive Lifesciences

Anivive Lifesciences is a software-driven pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable treatments for life-threatening diseases in pets. Through our proprietary AI platform, we are pioneering first-in-class therapeutics in Oncology, Antivirals, and Antifungal Vaccines, setting new standards for innovation and excellence in the industry. To learn more, visit anivive.com  

About Vidium

Vidium Animal Health, an Anivive company, is committed to advancing the understanding of disease to give pets the fullest lives possible. The company provides diagnostic tests to veterinary oncologists, general practitioners, and pet parents, and is passionate about identifying the genetic components of common and complex diseases, including cancer. Vidium was built on a foundation of unimpeachable science and is led by a knowledgeable and experienced team with extensive veterinary and clinical genomic roots. For more information, visit vidiumah.com

SOURCE Anivive Lifesciences Inc.